Programs
|
| Milestones
|
EYLEA
| •
| Submit sBLA to FDA for every 12-week dosing interval in neovascular age-related macular degeneration (wet AMD)
|
Dupixent
| •
| Submission for additional regulatory approvals in atopic dermatitis outside of the United States
|
•
| Regulatory agency decision on atopic dermatitis in the European Union
|
•
| Report results from Phase 3 asthma program in adults and adolescents
|
•
| Submit sBLA for asthma in adult/adolescent patients
|
•
| Initiate Phase 3 studies in pediatric patients in atopic dermatitis
|
Praluent
| •
| Complete ODYSSEY OUTCOMES study (with data expected in early 2018)
|
Kevzara
| •
| Submission for additional regulatory approvals and regulatory agency decisions on applications outside of the United States
|
Suptavumab (REGN2222; RSV-F Antibody)
| •
| Report results from Phase 3 study
|
REGN2810 (PD-1 Antibody)
| •
| Initiate Phase 3 study in cervical cancer
|
Fasinumab (NGF Antibody)
| •
| Initiate Phase 3 study in chronic low back pain
|
Nesvacumab/aflibercept (Ang2 Antibody co-formulated with aflibercept)
| •
| Report data from Phase 2 studies in DME (RUBY) and wet AMD (ONYX)
|
REGN2477 (Activin A Antibody)
| •
| Initiate Phase 2 study in patients with FOP
|
